Wedge Pharmaceuticals

Wedge Bio, also known as Wellezhibo, is a clinical-stage biotechnology company headquartered in Nanjing, China, specializing in the discovery and development of innovative antibody-based therapies for oncology and immunology. The company utilizes its proprietary antibody discovery and engineering platforms to build a robust pipeline of monoclonal and bispecific antibodies. Its lead candidate, LBL-007, is a monoclonal antibody targeting LAG-3 that has demonstrated promising clinical activity and is currently being evaluated in Phase 2 trials, supported by a strategic partnership with Chugai Pharmaceutical. Wedge Bio's broader portfolio includes several first-in-class or best-in-class programs targeting TIM-3, PD-L1/4-1BB, and GPRC5D/CD3. With a global R&D footprint spanning China and the United States, the company is positioned to address significant unmet medical needs in the global cancer immunotherapy market.